Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020
Lucas Scharf da Costa, Mohammed M. Alsultan, Ana L. Hincapie, Jeff J. Guo
Topics & Concepts
MedicineMedical prescriptionReimbursementWarfarinMedicaidPrescription drugPopulationDabigatranApixabanRivaroxabanMedicare Part DEmergency medicineFamily medicineInternal medicineEnvironmental healthPharmacologyHealth careAtrial fibrillationEconomicsEconomic growthAtrial Fibrillation Management and OutcomesBlood Pressure and Hypertension StudiesVenous Thromboembolism Diagnosis and Management